Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges.

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Myeloproliferative neoplasms (MPNs) encompass polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF).
• MPNs involve JAK/STAT pathway mutations and can progress to acute leukemia (MPN-blast phase, MPN-BP).
• MPN-BP is defined by ≥20% blasts, often preceded by an accelerated phase (MPN-AP) with 10-19% blasts.

Purpose of the Study:

• To review current management strategies for MPN-AP/BP.
• To discuss future therapeutic directions for MPN-AP/BP.
• To address the unmet need for effective treatments in advanced MPN phases.

Main Methods:

• Review of current literature on MPN-AP/BP.
• Analysis of molecular characteristics of MPN-AP/BP.
• Evaluation of existing and emerging therapies for MPN-AP/BP.

Main Results:

• MPN-AP/BP exhibit increased molecular complexity.
• Standard acute myeloid leukemia (AML) therapies show limited efficacy in MPN-AP/BP.
• Allogeneic hematopoietic stem cell transplant (HSCT) is curative but limited by toxicity and utilization.

Conclusions:

• MPN-AP/BP represent a critical unmet need in hematologic malignancies.
• Novel therapeutic approaches are essential for improving outcomes in MPN-AP/BP.
• Further research into targeted therapies and improved HSCT strategies is warranted.